ArQule, Inc. (ARQL) vs. Top 20 Hedge Fund Stocks in 2019
It has been a fantastic year for equity investors as Donald Trump pressured Federal Reserve to reduce interest rates and finalized the first leg of a trade deal with China.
Posts Tagged ‘(NASDAQ:ARQL)’
Hedge Funds Are Starting To Cash Out Of ArQule, Inc. (ARQL)
We can judge whether ArQule, Inc. (NASDAQ:ARQL) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas.
Hedge Funds Have Never Been This Bullish On ArQule, Inc. (ARQL)
Is ArQule, Inc. (NASDAQ:ARQL) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock.
Hedge Fund and Insider Trading News: Simon Sadler, Ray Dalio, George Soros, Neil Woodford, Warlander Asset Management, ArQule, Inc. (ARQL), Century Communities Inc (CCS), and More
If Blackpool supporters who fought the arduous campaign against Owen Oyston’s toxic ownership ever fantasised about the ideal alternative, they may have imagined a figure not...
Did Hedge Funds Drop The Ball On ArQule, Inc. (ARQL) ?
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much.
ArQule, Inc. (ARQL): Are Hedge Funds Right About This Stock?
Before we spend days researching a stock idea we'd like to take a look at how hedge funds and billionaire investors recently traded that stock.
13G Filing: Biotechnology Value Fund LP and Arqule Inc (ARQL)
Please follow Biotechnology Value Fund LP (if you aren't already doing so) to get real-time email alerts whenever we publish an article about Biotechnology Value Fund LP or update...
13G Filing: Biotechnology Value Fund L P and Arqule Inc (ARQL)
Please follow Biotechnology Value Fund LP (if you aren't already doing so) to get real-time email alerts whenever we publish an article about Biotechnology Value Fund LP or update...
ArQule, Inc. (ARQL)’s Liver Cancer Drug Fails: What’s Next?
ArQule, Inc. (NASDAQ:ARQL) took a real hit at the end of last week, as the company announced data from a late stage oncology trial.
How ArQule, Inc. (ARQL) Stacks Up Against Its Peers
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive...
Here’s What The ArQule, Inc. (ARQL) Data Really Means
We just got some interim data from ArQule, Inc.
Pfizer Inc (PFE) Reports 4.4% Position in Arqule Inc (ARQL)
Pfizer Inc. (NYSE:PFE) has reported holding a 4.4% position in microcap biopharmaceutical company ArQule, Inc. (NASDAQ:ARQL).
13G Filing: Nantahala Capital Management and Arqule Inc (ARQL)
A recent filing with the US Securities and Exchange Commission showed that Wilmot B.
Hedge Funds Are Selling BioDelivery Sciences International, Inc. (BDSI)
At the moment, there are many indicators market participants can use to watch their holdings. Two of the most under-the-radar are hedge fund and insider trading activity.
This Metric Says You Are Smart to Buy Amicus Therapeutics, Inc. (FOLD)
Now, according to many investors, hedge funds are assumed to be overrated, outdated investment tools of an era lost to time.
CONN’S, Inc. (CONN), ArQule, Inc. (ARQL), VIVUS, Inc. (VVUS): Last Week’s Biggest Losers
Let's start with CONN'S, Inc. (NASDAQ:CONN). The retailer of consumer electronics, appliances, and furniture slumped after missing estimates.
Pain Therapeutics, Inc. (PTIE): Are Hedge Funds Right About This Stock?
In the eyes of many investors, hedge funds are viewed as overrated, old investment vehicles of an era lost to time.
What Hedge Funds Think About ArQule, Inc. (ARQL)
In the 21st century investor’s toolkit, there are many metrics shareholders can use to monitor stocks.
What’s a Smart Cytokinetics, Inc. (CYTK) Investor To Do?
In the eyes of many of your peers, hedge funds are seen as useless, old investment tools of a forgotten age.
Hedge Funds Are Buying ZIOPHARM Oncology Inc. (ZIOP)
In the eyes of most stock holders, hedge funds are seen as underperforming, outdated financial vehicles of years past.
Cytokinetics, Inc. (CYTK): Hedge Funds Are Bullish and Insiders Are Bearish, What Should You Do?
Cytokinetics, Inc. (NASDAQ:CYTK) was in 8 hedge funds' portfolio at the end of March.
Hedge Funds Are Crazy About Cytokinetics, Inc. (CYTK)
Is Cytokinetics, Inc. (NASDAQ:CYTK) the right pick for your portfolio? Prominent investors are in a bullish mood.
Hedge Funds Are Buying Amicus Therapeutics, Inc. (FOLD)
Amicus Therapeutics, Inc. (NASDAQ:FOLD) was in 12 hedge funds' portfolio at the end of March.
Is BioDelivery Sciences International, Inc. (BDSI) Going to Burn These Hedge Funds?
BioDelivery Sciences International, Inc.
ArQule, Inc. (ARQL): Hedge Funds and Insiders Are Bearish, What Should You Do?
In today’s marketplace, there are plenty of indicators market participants can use to watch the equity markets.
Pain Therapeutics, Inc. (PTIE): Are Hedge Funds Right About This Stock?
Is Pain Therapeutics, Inc. (NASDAQ:PTIE) a buy, sell, or hold? The smart money is in a bearish mood.
Amicus Therapeutics, Inc. (FOLD): Are Hedge Funds Right About This Stock?
Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) a marvelous investment today? Money managers are becoming less confident.
Is ArQule, Inc. (ARQL) Going to Burn These Hedge Funds?: ShangPharma Corp (ADR) (SHP), OncoGenex Pharmaceuticals Inc (OGXI)
ArQule, Inc. (NASDAQ:ARQL) was in 13 hedge funds' portfolio at the end of December. ARQL investors should pay attention to a decrease in hedge fund sentiment in recent months.
